{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:37:29Z","timestamp":1790505449910,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T00:00:00Z","timestamp":1470614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA197120\u201001"],"award-info":[{"award-number":["1R01CA197120\u201001"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:p>The chronic lymphocytic leukemia International Prognostic Index (CLL\u2010IPI) combines 5 parameters (age, clinical stage, <jats:italic>TP53<\/jats:italic> status [normal vs. del(17p) and\/or TP53 mutation], <jats:italic>IGHV<\/jats:italic> mutational status, serum \u03b22\u2010microglobulin) to predict survival and time\u2010to\u2010first\u2010treatment (TTFT) in CLL patients. We performed an observational study in 337 prospectively collected, Binet stage A patients to validate the ability of the CLL\u2010IPI to predict TTFT in an independent cohort of early stage CLL patients. The CLL\u2010IPI score stratified Binet stage A patients into three subgroups with different outcome. Since the CLL\u2010IPI was originally developed to predict survival, we next investigated the optimal cut\u2010off score to predict TTFT in Binet stage A patients. Recursive partitioning analysis identified three subsets with scores of 0 (<jats:italic>n =<\/jats:italic> 139), 1 (<jats:italic>n =<\/jats:italic> 90), and\u2009\u2265\u20092(<jats:italic>n =<\/jats:italic> 108). The probability of remaining free from therapy 5 years after diagnosis was 85%, 67% and 46% in these three categories (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001.; <jats:italic>C<\/jats:italic>\u2010statistic:c\u2009=\u20090.72; 95% CI:0.58\u20100.81). This optimized CLL\u2010IPI scoring for TTFT was subsequently validated in an independent cohort of Binet A patients from the Mayo Clinic (<jats:italic>n =<\/jats:italic> 525). The ability of either original or optimized CLL\u2010IPI to predict TTFT was equivalent to other prognostic models specifically designed for this endpoint (2011 MDACC score and O\u2010CLL1 score). Although originally developed to predict suvival, the CLL\u2010IPI is useful for predicting TTFT in early stage CLL patients. Am. J. Hematol. 91:1090\u20131095, 2016. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24493","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T01:52:41Z","timestamp":1469670761000},"page":"1090-1095","source":"Crossref","is-referenced-by-count":74,"title":["The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients"],"prefix":"10.1002","volume":"91","author":[{"given":"Stefano","family":"Molica","sequence":"first","affiliation":[{"name":"Department of Oncology and Hematology Pugliese\u2010Ciaccio Hospital Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tait D.","family":"Shanafelt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Division of Hematology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[{"name":"Biostatistics Unit Regina Elena Institute for Cancer Research and Treatment Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"Hematology Unit Department of Onco\u2010Hematology a.O. Of Cosenza Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Mirabelli","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology Pugliese\u2010Ciaccio Hospital Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Cutrona","sequence":"additional","affiliation":[{"name":"SS Molecular Diagnostics IRCCS S. Martino\u2010IST Genova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Levato","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology Pugliese\u2010Ciaccio Hospital Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Di Renzo","sequence":"additional","affiliation":[{"name":"Hematology Unit Ospedale Vito Fazzi Lecce Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences Division of Haematology University of Catania and Ferrarotto Hospital Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Musolino","sequence":"additional","affiliation":[{"name":"Division of Haematology University of Messina Messina Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Angrilli","sequence":"additional","affiliation":[{"name":"Department of Hematology Ospedale Santo Spirito Pescara Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Fam\u00e0","sequence":"additional","affiliation":[{"name":"Division of Haematology Arcispedale S. Maria Nuova\/IRCCS Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Grazia","family":"Recchia","sequence":"additional","affiliation":[{"name":"Biotechnology Research Unit Azienda Sanitaria Provinciale Di Cosenza Aprigliano (CS, Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7313-1875","authenticated-orcid":false,"given":"Kari G.","family":"Chaffee","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Neri","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health University of Milano and Hematology CTMO, Milano, Italy, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Division of Hematology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlio","family":"Ferrarini","sequence":"additional","affiliation":[{"name":"San Martino IST Direzione Scientifica IRCCS Genova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[{"name":"Hematology Unit Department of Onco\u2010Hematology a.O. Of Cosenza Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature15395"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.8762"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1840"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V\u2010H genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin TJ","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-051458"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.9002"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-556399"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214346"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.333"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830290307"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-458265"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.8515"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27900"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805213382104"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.10.861"},{"key":"e_1_2_6_22_1","article-title":"Early versus deferred treatment with combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event\u2010Free Survival In Patients With High\u2010Risk Binet Stage A ChronicLymphocytic Leukemia \u2013 First Results Of a Randomized German\u2010 French Cooperative Phase III Trial","author":"Schweighofer CD","year":"2013","journal-title":"Am Soc Hematol"},{"key":"e_1_2_6_23_1","doi-asserted-by":"crossref","unstructured":"LangerbeinsP BahloJ RheinC et al. Ibrutinib in early stage CLL: preliminary results of a placebo controlled phase III study. ASH 57thAnnual Meeting and Exposition Orlando FL December 5\u20108 2015 abstr 2934.","DOI":"10.1182\/blood.V126.23.2934.2934"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25292"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-620864"},{"key":"e_1_2_6_26_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Non\u2010Hodgkin's Lymphomas. Version 2.2016.http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24493","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T17:36:51Z","timestamp":1695490611000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,8]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1002\/ajh.24493"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24493","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,8]]}}}